{"id":"https://openalex.org/W1586362467","doi":null,"title":"Dasatinib (Sprycel\u00ae) for the 1st-line treatment of Philadelphia-chromosome positive chronic myeloid leukemia in the chronic phase","display_name":"Dasatinib (Sprycel\u00ae) for the 1st-line treatment of Philadelphia-chromosome positive chronic myeloid leukemia in the chronic phase","alternate_titles":[],"publication_year":2011,"publication_date":"2011-01-01","ids":{"openalex":"https://openalex.org/W1586362467","mag":"1586362467"},"language":"en","primary_location":{"id":"mag:1586362467","doi":null,"is_oa":false,"landing_page_url":"http://eprints.aihta.at/910/","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"parent_works":[],"lineage":["https://openalex.org/W1586362467"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5057657400","display_name":"K. Hintringer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"K. Hintringer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5057657400"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.1775,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.52375989,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dasatinib","display_name":"dasatinib","score":1.0},{"id":"https://openalex.org/keywords/philadelphia-chromosome-positive-chronic-myeloid-leukemia","display_name":"Philadelphia chromosome-positive chronic myeloid leukemia","score":0.8849999904632568},{"id":"https://openalex.org/keywords/chronic-phase","display_name":"chronic phase","score":0.75},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.9660000205039978},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.8550000190734863},{"id":"https://openalex.org/keywords/imatinib","display_name":"imatinib","score":0.7940000295639038},{"id":"https://openalex.org/keywords/complete-cytogenetic-response","display_name":"complete cytogenetic response","score":0.9639999866485596},{"id":"https://openalex.org/keywords/blast-crisis","display_name":"blast crisis","score":0.7509999871253967},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.8600000143051147},{"id":"https://openalex.org/keywords/pleural-effusion","display_name":"pleural effusion","score":0.8870000243186951},{"id":"https://openalex.org/keywords/drug-approval","display_name":"drug approval","score":0.8069999814033508}],"concepts":[{"id":"https://openalex.org/C2779536868","wikidata":"https://www.wikidata.org/wiki/Q419940","display_name":"Dasatinib","level":4,"score":0.9897888898849487},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7989751100540161},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.7490463256835938},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6292223334312439},{"id":"https://openalex.org/C3019892230","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib mesylate","level":4,"score":0.5332325100898743},{"id":"https://openalex.org/C2778904597","wikidata":"https://www.wikidata.org/wiki/Q1129111","display_name":"Philadelphia chromosome","level":4,"score":0.5318728685379028},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.5294187664985657},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.49754956364631653},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.485159695148468},{"id":"https://openalex.org/C2777413986","wikidata":"https://www.wikidata.org/wiki/Q412327","display_name":"Nilotinib","level":4,"score":0.4781809151172638},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.41823461651802063},{"id":"https://openalex.org/C138626823","wikidata":"https://www.wikidata.org/wiki/Q916504","display_name":"Chromosomal translocation","level":3,"score":0.1253594160079956},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.09459984302520752},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0885695219039917},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0489121675491333},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:1586362467","doi":null,"is_oa":false,"landing_page_url":"http://eprints.aihta.at/910/","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2333107100","https://openalex.org/W2081056425","https://openalex.org/W2163773009","https://openalex.org/W2032591088","https://openalex.org/W2010090276","https://openalex.org/W2057206328","https://openalex.org/W2097799776","https://openalex.org/W2277535953","https://openalex.org/W2074762197","https://openalex.org/W2566861500"],"abstract_inverted_index":{"Dasatinib,":[0],"a":[1,40],"second":[2],"generation":[3],"tyrosine-kinase":[4],"inhibitor":[5],"(TKI),":[6],"reduces":[7],"the":[8,20,37,44,49,57,83,98,114,123,131,141,147,160,165,168,203,211,217],"proliferation":[9],"of":[10,46,52,86,97,202,214,220],"BCR-ABL":[11,21],"positive":[12,41,54],"chronic":[13,58],"myeloid":[14],"leukemia":[15],"(CML)":[16],"cells":[17],"by":[18],"inhibiting":[19],"pathway.":[22],"Since":[23],"2006":[24],"dasatinib":[25,47,67,102,124,148,161,183,215],"is":[26,72,103,117,170,195],"approved":[27],"for":[28,43,48,172],"2nd-line":[29],"leukaemia":[30],"therapy":[31,51,77,219],"in":[32,56,78,122,140,159,164,182,216],"Europe.":[33],"In":[34],"October":[35],"2010,":[36],"EMA":[38],"granted":[39],"opinion":[42],"approval":[45],"1st-line":[50,76,218],"Philadelphia-chromosome":[53],"CML":[55],"phase":[59,133],"(Ph+CML-CP).":[60],"\nThe":[61],"pivotal":[62],"DASISION":[63],"trial":[64,99],"investigates":[65],"whether":[66],"100mg":[68],"orally":[69,91],"once":[70,92],"daily":[71],"more":[73,105,138,157],"effective":[74,106],"as":[75],"Ph+":[79],"CML-CP":[80],"patients":[81],"than":[82,107,163],"current":[84],"standard":[85],"care":[87],"\u2013":[88],"imatinib":[89,126,166],"400mg":[90],"daily.":[93],"The":[95,109],"results":[96],"indicate":[100],"that":[101],"clinically":[104],"imatinib.":[108],"confirmed":[110],"complete":[111],"cytogenetic":[112],"response,":[113],"primary":[115],"endpoint,":[116],"77%":[118],"vs.":[119],"66%":[120],"(p=0.007)":[121],"and":[125,207],"groups,":[127],"respectively.":[128],"Progression":[129],"to":[130,146,197,208],"accelerated":[132],"or":[134],"blast":[135],"crisis":[136],"occurred":[137,156,180],"frequent":[139,158],"control":[142],"group":[143,149,162],"(3.5%)":[144],"compared":[145],"(1.9%).":[150],"Whereas,":[151],"haematological":[152],"adverse":[153],"events":[154],"(AEs)":[155],"group,":[167],"opposite":[169],"true":[171],"non-haematological":[173],"AEs":[174],"-":[175],"except":[176],"pleural":[177],"effusions,":[178],"these":[179,188],"only":[181],"treated":[184],"patients.":[185],"Despite":[187],"first":[189],"encouraging":[190],"interim":[191],"results,":[192],"further":[193,209],"follow-up":[194],"essential":[196],"provide":[198],"information":[199],"on":[200],"durability":[201],"responses,":[204],"quality-of-":[205],"life":[206],"investigate":[210],"safety":[212],"profile":[213],"CML.":[221]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1586362467","counts_by_year":[],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
